Ph 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint of Spleen Volume Reduction but not Abs-TSS March 31, 2026
FDA clears IND application for Ph 1 study for PRT12396 for the treatment of patients with myeloproliferative neoplasms February 9, 2026
Orphan Drug Designation Granted to OPN-2853 (Zavabresib) for the Treatment of Myelofibrosis January 25, 2026
FDA Grants Orphan Drug Designation to CK0804 Treg Therapy for Treatment of Myelofibrosis January 11, 2026
DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of VONJO® (pacritinib) July 19, 2023
